As a cataract surgeon in Southern California, Duna Raoof, MD, knows that her patients demand excellent visual quality that allows them independence from glasses. That’s why she relies on The Clareon® platform.
In my early experience so far with this lens, patients have been incredibly happy with the visual outcome. They are reporting excellent clarity of vision and excellent color perception.
The Clareon® lens not only is manufactured differently, but it’s also a progressed material that achieves better clarity and reduced glistening.1
The entire platform of Alcon premium lenses has been a game changer for my practice. I’m able to recommend these lenses with great confidence, knowing that I will be able to deliver excellent vision.2,3
See future issues and “Clareon® Collection of IOLs” on Eyetube to hear from more surgeons.
Important Product Information – Clareon™ Aspheric Hydrophobic Acrylic IOL with the AutonoMe™ Automated Pre-loaded Delivery System
CAUTION: Federal law restricts this device to sale by or on the order of a physician.
INDICATION: The Clareon™ Aspheric Hydrophobic Acrylic Intraocular Lens (IOL) is indicated for primary implantation in the capsular bag in the posterior chamber of the eye for the visual correction of aphakia in adult patients in whom a cataractous lens has been removed.
WARNINGS/PRECAUTIONS:
The Clareon™ IOL is intended for implantation in the capsular bag only. Physicians considering lens implantation under any of the following circumstances should weigh the potential risk/benefit ratio: Patients in whom the posterior capsule is ruptured, zonules are damaged, or primary posterior capsulotomy is planned.
DO NOT re-sterilize the Clareon™ IOL or the AutonoMe™ Delivery System by any method. DO NOT implant the IOL if the sterility has been compromised or if the sterile package has been unintentionally opened before use. DO NOT reuse the Clareon™ IOL or AutonoMe™ Delivery System. The device is for single use only.
The safety and effectiveness of the Clareon™ IOL has not been substantiated in clinical trials in patients with certain pre-existing conditions and/or intraoperative conditions (listed in Tables 4 and 5 of the Directions for Use).
As with any surgical procedure, there is risk involved. Potential complications accompanying cataract and/or IOL implantation surgery may include, but are not limited to, the following: lens epithelial cell on-growth, corneal endothelial cell damage, infection (endophthalmitis), toxic anterior segment syndrome (TASS), retinal detachment, vitritis, cystoid macular edema, corneal edema, pupillary block, cyclitic membrane, iris prolapse, hypopyon, anterior uveitis, hyphema, pigment dispersion, posterior capsule opacification, transient or persistent glaucoma, and secondary surgical interventions. Secondary surgical interventions include, but are not limited to: lens repositioning, lens replacement, vitreous aspiration or iridectomy for pupillary block, wound leak repair, and retinal detachment repair.
ATTENTION: Refer to the Directions for Use labeling for a complete list of indications, warnings and precautions.
1. Lehmann R. Clin Ophthalmol. 2021;15:1647-1657.
2. Clareon® PanOptix® Trifocal Hydrophobic Acrylic IOL. Directions for Use.
3. Zhu D. Ophthalmol Ther. 2023;12(2):1157-1171.
© 2024 Alcon Inc. 02/24 US-CLI-2400021
Clareon trademark information. All other brand/product names are the trademarks of their respective owners.
